Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intranasal SB-705498 in Non-allergic Rhinitis Patients

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: August 25, 2011
Last updated: March 22, 2012
Last verified: March 2012

August 25, 2011
March 22, 2012
December 2009
April 2010   (final data collection date for primary outcome measure)
Symptom scores and ipsilateral secretion weights [ Time Frame: 0-4hours following dosing ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01439308 on Archive Site
  • Peak nasal inspiratory flow changes after challenge [ Time Frame: 0-4hours following dosing ] [ Designated as safety issue: Yes ]
  • Biomarker levels in the nasal samples [ Time Frame: 0-4hours following dosing ] [ Designated as safety issue: No ]
  • Blood levels of drug [ Time Frame: 0-4hours following dosing ] [ Designated as safety issue: No ]
  • Number of subjects with adverse events [ Time Frame: Day 1 ] [ Designated as safety issue: Yes ]
  • Symptom scores and contralateral secretion weights [ Time Frame: 0-4hours following dosing ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Intranasal SB-705498 in Non-allergic Rhinitis Patients
A Randomized, Double Blind, Placebo Controlled Study to Assessthe Effect of Intranasal Single Dose SB-705498 on the Response Tointranasal Capsaicin Challenge in Non-allergic Rhinitis Patients
This study is designed to look at the affect of SB-705498 on rhinitis symptoms, as induced by capsaicin challenge
Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Non-allergic Rhinitis
  • Rhinitis
  • Drug: Placebo
    SB-705498 placebo
  • Drug: SB-705498
    12mg intranasal SB-705498
  • Placebo Comparator: Arm 1
    3 incremental capsaicin doses
    Intervention: Drug: Placebo
  • Active Comparator: Arm 2
    3 incremental capsaicin doses
    Intervention: Drug: SB-705498
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • NAR patients
  • Male or female between 18 and 60 years of age inclusive.
  • Non-child bearing women or women of child bearing potential if they agree to use contraception as indicated by the protocol
  • Non-smoker for at least 6 months with a pack history <5 pack years (Pack years = (No. of cigarettes smoked/day/20) x No. of years smoked).
  • Body weight > 50 kg and body mass index (BMI) within the range 19 - 29.9 kg/m2 (inclusive).
  • Capable of giving written informed consent.
  • Available to complete all the required study measurements.
  • Normal 12-lead ECG at screening.
  • Subject must demonstrate reactivity to unilateral, intranasal challenge with the selected single dose of capsaicin, defined as development of TSS ≥ 3.
  • Normal levels of total plasma IgG and negative allergy skin or Rast test to common aeorallergens.
  • Good general health, apart from NAR, as determined by a responsible physician.

Exclusion Criteria:

Past medical history of allergic rhinitis or rhinosinusitis.

  • Nasal conditions likely to affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, other nasal malformations.
  • A history of gastrointestinal, hepatic, renal or multiple cardiovascular risk factors.
  • Positive pre-study drug/alcohol screen.
  • Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  • A positive test for human immunodeficiency virus (HIV) antibody (if determined by the local standard operating procedures (SOPs)).
  • History of regular alcohol consumption within 6 months of the study.
  • Exposure to more than four new chemical entities within 12 months prior to the start of the study.
  • Participation in a clinical trial with a new molecule entity or any other clinical trial within 4 months of the start of the study.
  • Use of prescription or non-prescription drugs, as well as of vitamins, herbal and dietary supplements (including St John's Wort) within 2 days prior to each study visit in Part 1 of the study or 14 days prior to the first treatment administration in Part 2 of the study.
  • Inability to abstain from all intranasal or oral medication to treat nasal symptoms from the first capsaicin challenge to the completion of the study including: sodium cromoglycate, antihistamines, anticholinergics, alpha-adrenergic agonists and corticosteroids
  • History of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation.
  • Subjects demonstrating hypersensitivity to the placebo capsaicin challenge at baseline screening.
  • Donation of blood or blood products in excess of 500mL within a 56 day period prior the start of Part 2 of this study.
  • Pregnant females as determined by positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Nicotine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • For Part 2 only: Subjects with known lactose intolerance.
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP